Provider Alert! Changes to Lovaza Clinical Prior Authorization Scheduled for March 21, 2023
Date: February 15, 2023
Attention: Providers
Effective Date: March 21, 2023
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: The Texas Health and Human Services (HHS) will revise the Lovaza clinical prior authorization criteria guide to include any covered omega-3 fatty acids drugs.
How this impacts providers:
● The title of the prior authorization criteria guide will change from Lovaza to Omega-3 Fatty Acids.
● The criteria will change by adding manual steps to check for the severity of hypertriglyceridemia.
● Lovaza will be approved for patients diagnosed with severe hypertriglyceridemia
● Vascepa will be approved for patients diagnosed with severe or elevated triglycerides.
Updated Omega-3 fatty acids prior authorization form can be found here.
For access to all prior authorization forms and formulary, visit: https://txstarchip.navitus.com/ and click “Prior Authorizations”
If you have any questions, please email TCHPPharmacy at: TCHPPharmacy@texaschildrens.org
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.
